Renal Clear Cell 
No Prior Systemic Therapy 
Nephrectomy Candidate 
IRB# 19991 A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] 
IRB# 19661 EA8143: Phase 3 RandOMized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER) 
No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor 
IRB# 19283 Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC 
IRB# 17027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology 
IRB# 11804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembro 
Prior Systemic Therapy 
Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 
Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies 

Renal Non-Clear Cell 
Papillary Renal Carcinoma 
IRB#16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib 

Localized 
T1b or greater (has not spread beyond the kidney) 
Clear Cell 
Nephrectomy Candidate 
IRB# 19991 A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] 
IRB# 19661 EA8143: Phase 3 RandOMized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER) 
No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor 
IRB# 19283 Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC 
IRB# 17027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology 
IRB# 11804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembro 
Prior Systemic Therapy 
Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 
Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies 

Metastatic/locally advanced 

CROSS-DISEASE TRIALS
IRB# 19992 New study coming soon
IRB# 18084 S1609 (DART)

08/06/19

http://www.ohsu.edu/research/rda/so/knight.php